- Home
- SONO vs ICUCW Comparison
SONO vs ICUCW Comparison
Compare SONO & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- ICUCW
- Stock Information
- Founded
- SONO 2002
- ICUCW N/A
- Country
- SONO United States
- ICUCW United States
- Employees
- SONO N/A
- ICUCW 12
- Industry
- SONO Consumer Electronics/Video Chains
- ICUCW Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- ICUCW Health Care
- Exchange
- SONO Nasdaq
- ICUCW Nasdaq
- Market Cap
- SONO 951.5M
- ICUCW N/A
- IPO Year
- SONO 2018
- ICUCW 2021
- Fundamental
- Price
- SONO $9.45
- ICUCW $0.03
- Analyst Decision
- SONO Buy
- ICUCW
- Analyst Count
- SONO 3
- ICUCW 0
- Target Price
- SONO $14.00
- ICUCW N/A
- AVG Volume (30 Days)
- SONO 2.4M
- ICUCW N/A
- Earning Date
- SONO 05-07-2025
- ICUCW N/A
- Dividend Yield
- SONO N/A
- ICUCW N/A
- EPS Growth
- SONO N/A
- ICUCW N/A
- EPS
- SONO N/A
- ICUCW N/A
- Revenue
- SONO $1,456,044,000.00
- ICUCW N/A
- Revenue This Year
- SONO N/A
- ICUCW N/A
- Revenue Next Year
- SONO $5.73
- ICUCW N/A
- P/E Ratio
- SONO N/A
- ICUCW N/A
- Revenue Growth
- SONO N/A
- ICUCW N/A
- 52 Week Low
- SONO $7.63
- ICUCW N/A
- 52 Week High
- SONO $18.02
- ICUCW N/A
- Technical
- Relative Strength Index (RSI)
- SONO 49.93
- ICUCW N/A
- Support Level
- SONO $7.63
- ICUCW N/A
- Resistance Level
- SONO $8.12
- ICUCW N/A
- Average True Range (ATR)
- SONO 0.46
- ICUCW 0.00
- MACD
- SONO 0.27
- ICUCW 0.00
- Stochastic Oscillator
- SONO 97.33
- ICUCW 0.00
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.